Direct answer first: ketamine is not an established treatment for anxiety disorders. No regulator has approved ketamine or esketamine for any anxiety indication, there is no adequate randomised controlled trial in generalised anxiety disorder, and the research that does exist is small, short and preliminary. This page exists because clinics advertise ketamine for the treatment of anxiety disorders anyway, and because the honest version of the evidence is hard to find between marketing on one side and dismissal on the other. We map what has actually been studied, what off-label means in this context, and which doors with real evidence behind them deserve a first or second look before anything experimental.
TL;DR With no formal approval or a large-scale RCT in GAD, there are only a handful of small, short studies in treatment-resistant anxiety with short-lived effects. Anxiety relief seen in ketamine depression trials happens in people being treated for depression who have comorbid anxiety symptoms and does not establish efficacy in primary anxiety disorders. The evidence-based path for anxiety treatment remains exposure-based CBT and medications such as SSRIs, SNRIs and benzodiazepines. If a clinic offers ketamine treatments for anxiety, questions like "on what evidence?" and "what have I not yet properly tried?" are appropriate.
What has actually been studied
The anxiety-specific ketamine literature is fairly sparse compared with studies in depression. A New Zealand research group ran brief controlled and open-label studies of ketamine in treatment-resistant generalised and social anxiety disorder: single doses or short series, small samples (a dozen to a few dozen participants), anxiolytic effects that appeared within hours and faded over days to a week or two, and dose-related dissociation during administration (Glue et al. 2017; Glue et al. 2019). A small randomised trial in social anxiety disorder found short-term symptom reduction against placebo (Taylor et al. 2018). There are case series and open studies beyond these, and a broader review literature that consistently reaches the same verdict: signals worth researching, nothing approaching the evidence that regulators or guidelines require (Whittaker et al. 2021, systematic review).
These preliminary studies suggest that ketamine may produce rapid reductions in anxiety symptoms in some patients with treatment-resistant GAD or social anxiety disorder. Repeated-administration studies have also explored whether these improvements can be maintained. However, the small samples, limited control conditions and restricted follow-up prevent firm conclusions about the durability of benefit, optimal dosing frequency, relapse prevention or long-term safety.
Importantly, several significant gaps remain in the evidence. Although small controlled studies have investigated ketamine for treatment-resistant generalised anxiety disorder, larger, adequately powered randomised controlled trials are needed to establish its efficacy. Evidence is also insufficient to determine whether repeated dosing provides sustained benefits or to establish the long-term safety of ketamine for anxiety disorders. Consequently, ketamine is not currently recommended as a treatment for primary anxiety disorders in major clinical guidelines, including those from NICE and relevant German guideline bodies.
One source of confusion should also be highlighted. Ketamine depression trials often record improvements in anxiety symptoms, and clinic marketing recycles those numbers as "ketamine works for anxiety". These are secondary observations in people selected and treated for depression. Anxiety in depressive disorders is not the same as generalised anxiety disorder, and a secondary endpoint in one condition is not an evidence base for another.
Off-label here means further off the map
Racemic ketamine can be legally prescribed off-label when a licensed physician takes medical responsibility for the patient's treatment options. For depression, an off-label prescription at least stands on clinical trial literature. However, for anxiety disorders, the same prescription stands on small pilot studies.
Esketamine's EU label is depression-specific (treatment-resistant depression with an oral antidepressant, plus a short-term psychiatric-emergency indication) and includes no anxiety disorder.
A service providing ketamine for anxiety should be able to answer three questions: what evidence supports the indication, what the treatment plan is when effects fade, potentially within days, and why other established anxiety treatments have been ruled out first. Hesitation on any of the three is your answer. Our guide to choosing a clinic covers the screening, monitoring and governance questions that apply to any ketamine service.
The current approved treatment approaches have the strongest evidence
Anxiety disorders are among the best-treatable conditions in psychiatry, and also among the most under-treated.
Cognitive behavioural therapy is a well-established psychological treatment for anxiety disorders, although the techniques differ according to diagnosis. Exposure-based approaches are central to treating panic disorder and social anxiety disorder, while CBT for GAD often focuses on excessive worry, intolerance of uncertainty and associated cognitive and behavioural patterns. Applied relaxation is also an evidence-based option for GAD.
First-line medication (an SSRI or SNRI at adequate dose and duration) is the guideline pharmacological start, with defined next steps after non-response.
If your anxiety has "failed treatment", the first question is the same one we ask on every page of this site: what exactly was delivered, at what dose, for how long? A written answer to that question does more for your next appointment than any infusion.
If your anxiety lives alongside depression
The genuinely open door sits one condition over. If you also have depression that has not responded to two adequate antidepressant courses in the current episode, the treatment-resistant depression pathway exists with real evidence and, for esketamine, an EU label and reimbursement in many systems. Anxiety symptoms often improve when depression is treated.
However, treatment for depression requires a different clinical assessment, rather than being seen as a workaround: the indication is the depression, and the decision belongs to a prescriber against the label. Our depression options guide maps that ladder, and the eligibility check sorts out which routes are realistic where you live. Importantly, this is an orientation tool, not a diagnosis.
Trials
Clinical trials studying ketamine as the primary indication are rare in Europe; most research efforts with similar drugs sit in depression, PTSD and OCD. Registries move faster than any page: ClinicalTrials.gov and CTIS are the places to look, and our trials guide explains phases, placebo and consent. Trials are voluntary, ethics-supervised and free; screening is strict, and the study team decides eligibility.
Frequently asked questions
Does ketamine work for anxiety?
Small, short studies in treatment-resistant generalised and social anxiety found rapid, short-lived anxiolytic effects. However, there is no formal phase 3 RCT in GAD, no durability data and no approval. That is a research signal, not a treatment.
Why do clinics offer it then?
Because ketamine can be prescribed legally off-label for mental health conditions based on a medical practitioner's confidence that it is a viable treatment approach, patient demand is real, and anxiety numbers from depression trials make persuasive marketing. However, "legal prescription" and "evidence-based" are different claims. Ask any clinic offering it what trial evidence supports ketamine for your diagnosis specifically.
Is esketamine (Spravato) approved for anxiety?
No. Its EU label covers treatment-resistant depression together with an oral antidepressant (e.g. SSRI/SNRI), and a separate short-term psychiatric-emergency indication for acute suicidality. No anxiety disorder appears in the formal label for Spravato.
What should I try first?
Clinical guidelines recommend starting with evidence-based treatments, including cognitive behavioural therapy (CBT) with exposure techniques, delivered by a suitably trained therapist, and/or medication such as an SSRI or SNRI. These approaches can be used individually or in combination, depending on your symptoms, preferences and treatment history.
Importantly, both therapy and medication need to be delivered at an appropriate intensity and for a sufficient duration to assess their effectiveness. Inadequate treatment is common, and an unsuccessful attempt does not necessarily mean the approach will not work. Before considering experimental treatments, it is worth ensuring that established options have been properly explored, with a clear plan for what to try next if the initial treatment is ineffective.
Sources
- Glue et al. (2017) — ketamine in treatment-resistant generalised and social anxiety: dose-response
- Glue et al. (2019) — maintenance ketamine in treatment-resistant anxiety: extension study
- Taylor et al. (2018) — ketamine for social anxiety disorder: randomised crossover trial
- Whittaker et al. (2021) — systematic review: ketamine in anxiety disorders
- EMA — Spravato product information (licensed indications)
- NICE CG113 — generalised anxiety disorder and panic disorder: management
- MHRA — off-label or unlicensed use of medicines: prescribers' responsibilities
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.